Clinical Education · Modern Medicine

Obesity — The Complete Medical Guide

An evidence-based explainer covering definition, causes, biology, diagnosis, and every modern treatment — plus their side effects. Written for patients who want the full picture.

✓ WHO Aligned ✓ ICD-11 ✓ India-Specific
01 · Definition

What is Obesity?

The formal clinical definition used worldwide.

Obesity is a chronic, complex, relapsing disease where excessive body-fat accumulation harms health. It is formally recognised by the WHO, AMA, and NIH as a medical condition — not a willpower issue.

The WHO defines it as BMI ≥ 30 kg/m² in adults. For Asian Indians, cut-offs are lower because of higher visceral fat at lower BMI: overweight ≥ 23, obesity ≥ 25.

Calculate My BMI →

ICD-11 Code

5B81

Obesity due to energy imbalance.


Sub-classes

5B81.0 Class I · 30–34.9
5B81.1 Class II · 35–39.9
5B81.2 Class III · ≥ 40

02 · BMI Calculator

Check Your BMI — Free & Instant

Uses Asian-Indian cut-offs by default. Enter height and weight for an instant reading.

Your BMI
Enter values
Underweight < 18.5 Low
Normal 18.5 – 22.9* Healthy
Overweight 23.0 – 24.9* Increased
Obesity I 25.0 – 29.9* Moderate
Obesity II 30.0 – 34.9* Severe
Obesity III ≥ 35* Very Severe

* Asian-Indian cut-offs (South Asian Consensus Statement)

890M+
Adults globally with obesity
1 in 4
Indian urban adults affected
13
Cancers linked to obesity
2.8M
Deaths each year worldwide
03 · Causes

Why Obesity Develops

Tap each cause to expand. Most patients have 3–5 of these working together.

04 · Pathophysiology

The Biology — Step by Step

How energy imbalance becomes systemic metabolic disease.

1

Energy Imbalance

Caloric intake exceeds expenditure. Excess shuttled toward storage.

2

Adipocyte Expansion

Fat cells undergo hypertrophy and hyperplasia, especially in visceral depots.

3

Adipose Dysfunction

Hypoxic, stressed fat cells secrete TNF-α, IL-6; leptin rises, adiponectin falls.

4

Insulin Resistance

Ectopic lipid in liver and muscle impairs insulin signalling; compensatory hyperinsulinaemia.

5

Metabolic Disease

T2DM, dyslipidaemia, hypertension, NAFLD, CVD and certain cancers emerge.

Leptin ↑Resistance develops; satiety fails.
Ghrelin ↑Heightened hunger, post-diet.
Insulin ↑Compensatory → resistance.
Cortisol ↑Visceral fat deposition.
05 · Consequences

Diseases Linked to Obesity

Obesity is a root cause of over 200 health conditions.

Neurological

Stroke, dementia, depression, migraine.

Cardiovascular

Hypertension, CAD, heart failure, AFib.

Hepatic

NAFLD, NASH, cirrhosis, liver cancer.

Metabolic

T2DM, dyslipidaemia, metabolic syndrome, gout.

Reproductive

PCOS, infertility, ED, pregnancy risks.

Musculoskeletal

Knee OA, hip OA, back pain, reduced mobility.

Respiratory

OSA, hypoventilation, asthma flares.

Oncologic

Breast, endometrial, colon, kidney cancers.

06 · Diagnosis

Clinical Workup

A complete assessment combines anthropometry, blood work, and system evaluation.

Anthropometry

Body Composition

  • BMI
  • Waist circumference
  • WHR
  • Body-fat % (BIA/DEXA)
Metabolic

Glycaemia

  • Fasting glucose
  • HbA1c
  • OGTT
  • HOMA-IR
Lipid & Liver

Risk

  • Lipid profile
  • LFTs
  • Liver ultrasound
  • Uric acid
Endocrine

Hormones

  • TSH
  • Cortisol
  • LH/FSH, testosterone
  • Vit D
CV

Heart

  • BP
  • ECG
  • Echo
  • hs-CRP
Sleep

OSA Screen

  • STOP-BANG
  • Epworth scale
  • Polysomnography
Psych

Mental Health

  • PHQ-9
  • GAD-7
  • Binge-eating screen
Imaging

Advanced

  • DEXA
  • MRI fat
  • Calcium score
07 · Treatment

Modern Allopathic Management

A stepped-care model. Tap tabs below to see each tier.

First-Line

Lifestyle Modification

Foundation of every plan — mandatory first step.

Dietary Intervention
500–750 kcal/day deficit
Mediterranean, DASH, low-carb, or intermittent-fasting patterns. Target 5–10% body-weight loss over 6 months.
Physical Activity
≥ 150 min/week moderate
Plus 2–3 sessions/week resistance training to preserve lean mass during weight loss.
Behavioural Therapy
CBT, self-monitoring
Structured programmes produce sustained ~5–7% weight loss.
Sleep & Stress
≥ 7 h/night, mindfulness
Addresses cortisol-driven visceral fat deposition.
Second-Line

Pharmacotherapy

BMI ≥ 30, or ≥ 27 with comorbidity.

Semaglutide / Liraglutide
GLP-1 agonists
Slow gastric emptying, enhance satiety. 12–17% loss at 68 weeks (semaglutide 2.4 mg).
Tirzepatide
GIP/GLP-1 dual agonist
Newest class. Up to 20–22% weight loss. Weekly injection.
Orlistat
Lipase inhibitor
Blocks ~30% dietary fat absorption. 3–5% loss. Available OTC in some regions.
Phentermine-Topiramate
Sympathomimetic + GABA
Reduces appetite, enhances satiety. ~9% loss.
Naltrexone-Bupropion
Opioid antag + DNRI
Targets reward and hypothalamic centres. ~5% loss.
Setmelanotide
MC4R agonist
For rare monogenic obesity only.
Third-Line

Bariatric Surgery

BMI ≥ 40 (Asian ≥ 37.5), or ≥ 35 with comorbidity (Asian ≥ 32.5).

Roux-en-Y Gastric Bypass
Restrictive + malabsorptive
Gold standard. 60–80% excess weight loss. Strong T2DM remission.
Sleeve Gastrectomy
Restrictive
Most common worldwide. ~55–70% excess loss. Lower complication rate.
Adjustable Gastric Band
Restrictive
Reversible; declining use due to lower efficacy.
Biliopancreatic Diversion
Malabsorptive
Most aggressive. 70–80% excess loss. High deficiency risk.
Endoscopic Options
Balloon, ESG
Non-surgical alternatives. Temporary or scarless.
08 · Side Effects

Risks & Adverse Effects

Every pharmacological and surgical intervention has a risk profile. Know before you decide.

GLP-1 Agonists
Semaglutide, Liraglutide, Tirzepatide
Common
Common

Nausea, vomiting, diarrhoea, constipation, abdominal pain, injection-site reaction, muscle loss.

Serious / Rare

Acute pancreatitis, gallbladder disease, medullary thyroid carcinoma (black-box in rodents), retinopathy worsening.

Orlistat
Lipase inhibitor
Common
Common

Oily stools, faecal urgency, flatus with discharge, steatorrhoea, fat-soluble vitamin malabsorption.

Serious / Rare

Hepatotoxicity (rare), oxalate nephropathy, drug interactions (warfarin, cyclosporine, levothyroxine).

Phentermine-Topiramate
Sympathomimetic + GABA
Serious
Common

Dry mouth, paraesthesia, dizziness, dysgeusia, insomnia, cognitive slowing.

Serious / Rare

Teratogenic (cleft palate — contraindicated in pregnancy), tachycardia, glaucoma, metabolic acidosis, kidney stones.

Naltrexone-Bupropion
Opioid antag + DNRI
Serious
Common

Nausea, headache, constipation, dizziness, insomnia, dry mouth.

Serious / Rare

Seizures, hypertensive crises, suicidal ideation (black-box), hepatotoxicity, serotonin syndrome with SSRIs.

Gastric Bypass (RYGB)
Restrictive + malabsorptive surgery
Serious
Common

Dumping syndrome, vitamin deficiencies (B12, iron, D), hair loss, dehydration.

Serious / Rare

Anastomotic leak, internal hernia, marginal ulcer, gallstones, weight regain. 30-day mortality 0.3–0.5%.

Sleeve Gastrectomy
Restrictive surgery
Serious
Common

Nausea, vomiting, reflux/GERD (often worsens), B12 and iron deficiency.

Serious / Rare

Staple-line leak, bleeding, stricture, portal vein thrombosis; severe GERD may need conversion.

Gastric Band
Restrictive surgery
Common
Common

Nausea, vomiting, reflux, dysphagia, food intolerance, repeated adjustments.

Serious / Rare

Band slippage, erosion, port infection, oesophageal dilatation; often requires removal.

Intragastric Balloon
Endoscopic
Rare
Common

Nausea, vomiting, abdominal cramping, reflux.

Serious / Rare

Deflation and migration, bowel obstruction, gastric perforation, hyperinflation (rare deaths reported).

Important: All pharmacological therapies require long-term use to maintain weight loss. On discontinuation, most patients regain significant weight. Bariatric surgery is more durable but requires lifelong nutritional monitoring.
09 · FAQ

Frequently Asked Questions

Is obesity really a disease?
Yes. The WHO, AMA, NIH, and most global medical bodies formally classify obesity as a chronic, complex, relapsing disease with its own ICD-11 code (5B81). It is not a cosmetic issue or a matter of willpower.
Why are Indian BMI cut-offs lower?
Asian Indians develop more visceral fat and metabolic complications at lower BMIs compared to Europeans. The Indian consensus statement defines overweight at ≥ 23 and obesity at ≥ 25 kg/m².
Do weight-loss drugs work permanently?
No. GLP-1 agonists like semaglutide and tirzepatide produce impressive loss while on treatment, but most patients regain significant weight within 1 year of stopping. Long-term use is usually required.
Is bariatric surgery safe?
Modern laparoscopic bariatric surgery has a 30-day mortality rate of 0.1–0.5% — comparable to gallbladder surgery. It is generally very safe in experienced centres, but carries risks of leaks, deficiencies, and long-term complications.
Can Ayurveda help with obesity?
Ayurveda views obesity as Medoroga — a disorder of Medas dhatu and Kapha dosha. Classical Shodhana and Shamana therapies, combined with diet, activity and specific herbs, can support sustainable weight loss alongside modern care. AyuSlim is built on this integrative model.
What is the safest long-term approach?
Evidence consistently supports a combination of sustained lifestyle modification (diet + movement + sleep + stress), regular medical follow-up, and — where appropriate — adjunctive therapies. The safest approach is individualised under qualified supervision.
A Complementary Path

Ayurveda Meets Modern Science

AyuSlim combines time-tested Ayurvedic formulations with modern clinical understanding of obesity — supporting, not replacing, your medical care.

Medical Disclaimer: This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Obesity management must be individualised under a qualified physician. Do not start, stop, or modify any medication without medical consultation.